Vibrant Gastro

What Vibrant Gastro does

Vibrant Gastro is a privately held medical technology company that develops and sells a prescription-only, FDA-cleared, drug-free treatment system for adults with chronic idiopathic constipation (CIC). Founded in 2007 and headquartered in Austin, Texas with an Israeli parent entity in Yokne'am Illit, the company has built its commercial presence almost entirely in the US market following FDA marketing authorization in August 2022.

The company's core product, the Vibrant System, is built around a proprietary technology called the Synchronized Activation Method. The system comprises three integrated components: (1) a multi-use activation Pod that programs and wirelessly connects to the Vibrant Cloud via cellular networks; (2) a disposable vibrating capsule, taken orally at bedtime up to 5 nights per week, that mechanically stimulates the colon approximately 8 hours after ingestion to leverage the gut-brain connection and the colon's circadian rhythm; and (3) a mobile companion app for treatment tracking, available on iOS and Android with integrations to Apple Health and Google Health Connect. Clinical evidence supporting the system includes a 312-patient Phase 3 trial across more than 90 US centers, five additional multicenter studies totaling nearly 800 patients, and real-world data from more than 2,000 patients, with peer-reviewed publications in Gastroenterology, Nature Communications, and The Lancet/ECLINM.

Vibrant operates a hybrid prescription medical device business model. New patients receive a one-time Vibrant Starter Kit (containing the Pod plus a one-month supply of 20 capsules, NDC 60009-0189-82) and then transition to recurring monthly refills of capsules (NDC 60009-189-80), producing a razor-and-blade dynamic. Pricing is not publicly disclosed; fulfillment runs through MedOptions Rx specialty pharmacy (effective June 15, 2026) and the Federal Supply Schedule contract (FSS Contract #36F79725D0174) for VA and federal health patients. Go-to-market is sales-led via clinician engagement, EHR prescription integration requiring ICD-10 code K59.04, peer-reviewed publication, conference presence (DDW, ACG), and patient assistance programs. The company has raised $25M cumulatively since 2007, including a $7.5M Series E in March 2021 led by Unorthodox Ventures with Sequoia participation.

Name

Vibrant Gastro

Legal name

Vibrant Gastro, Inc.

Website

https://vibrantgastro.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Vibrant Gastro sells a prescription-only, FDA-cleared vibrating capsule system for adults with chronic idiopathic constipation. Its Synchronized Activation Method mechanically stimulates the colon via the gut-brain connection. Revenue comes from a starter kit plus recurring monthly capsule refills distributed via US specialty pharmacy.

Ownership category

akta.pro rank

Product category

Gastroenterology Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Gastrointestinal & Digestive Health (HLAIADAD)

Keywords

• Gastrointestinal medical devices
• Constipation treatment systems
• Vibrating capsule therapy
• Prescription digital therapeutics
• Drug-free gastroenterology devices

Headquarters

HQ city

Yoqne`am `illit

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Vibrant Starter Kit: New patients receive a Vibrant Starter Kit containing: a multi-use activation Pod, one month's supply (20 capsules) of disposable vibrating capsules, and instructions to download the companion app. This is a one-time purchase for the Pod component plus initial supply.
2. Vibrant Capsule Refills: Ongoing prescription refills of 20 capsules per month (recommended dose: 5 nights per week). Refills are shipped monthly as clinically appropriate. Distributed through MedOptions Rx specialty pharmacy partner.
3. Patient Assistance Programs: Vibrant Gastro offers Patient Assistance Programs (PAPs) administered through MedOptions Rx that provide financial assistance for out-of-pocket expenses. Eligibility determined via soft credit check through Experian Health.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Vibrant Gastro develops, manufactures, and sells the Vibrant System, a prescription-only, FDA-cleared (August 2022) drug-free medical device for adults with chronic idiopathic constipation (CIC). The system consists of an orally-administered single-use vibrating capsule programmed by a reusable activation Pod, supported by the Vibrant Companion mobile app. Treatment is prescribed by clinicians and fulfilled through specialty pharmacy partner MedOptions Rx, with monthly capsule refills providing recurring revenue.

Product overview

Vibrant Gastro offers the Vibrant System, a first-in-class, drug-free treatment for chronic idiopathic constipation. The system comprises three integrated components: the Vibrant Capsule (an orally-administered vibrating pill), the Vibrant Pod (a reusable activation device), and the Vibrant Companion App (mobile application for treatment tracking). The Synchronized Activation Method powers the system, using micro-vibrations to mechanically stimulate the colon via the gut-brain connection. Patients receive the Vibrant Starter Kit upon prescription, and ongoing refills of 20 capsules (one-month supply) are provided through specialty pharmacy partner MedOptions Rx. The VibrantConnect Program provides integrated patient support, insurance navigation, and care coordination.

Differentiator

Problem solved

Functional benefit

Brands

• Vibrant System™: The core drug-free treatment system comprising a vibrating capsule, activation pod, and companion app for chronic idiopathic constipation treatment.
• VibrantConnect Program

Quantifiable outcome

• 39.26% of patients had one or more additional complete spontaneous bowel movements (CSBMs) per week vs. 22.15% in placebo group (p<0.0001)
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Partnerships

One partnership is on record.

• MedOptions Rx LLCcoreChannel Partner/ Reseller/ DistributorSpecialty pharmacy partner handling all prescriptions, patient onboarding, insurance verification, and home delivery of Vibrant products. Contact: 866-359-7532 (option 2), NPI 1699667147, 450 E Devon Ave, Ste 170, Itasca, IL 60143. Effective June 15, 2026, MedOptions Rx becomes the sole specialty pharmacy partner, succeeding the previous partner Eversana. The PMDCP program will be sunsetted September 30, 2026.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Ironwood Pharmaceuticals: Ironwood developed Linzess (linaclotide), one of the leading prescription therapies for chronic idiopathic constipation and IBS-C. Direct competitor targeting the same gastroenterology prescribers and patient population with a similar reimbursement-driven, prescription-only model.
• Bausch Health (Salix Pharmaceuticals): Salix, the gastroenterology specialty arm of Bausch Health, markets Trulance (plecanatide) for chronic idiopathic constipation and IBS-C. Direct prescription competitor with deep GI specialty pharmacy relationships and a similarly focused commercial model.
• Ardelyx: Ardelyx markets IBSRELA (tenapanor) for IBS-C, addressing the same patient population and prescriber base as Vibrant with a differentiated mechanism. A focused specialty GI competitor at a similar scale and commercialization stage, providing direct read-across on payer dynamics.

Broad incumbents

• AbbVie: AbbVie co-markets Linzess with Ironwood for CIC and IBS-C, and operates one of the largest gastroenterology sales forces in the industry. A broad incumbent in the same therapeutic area with substantially greater commercial scale and payer leverage than Vibrant.
• Takeda Pharmaceutical: Takeda markets Amitiza (lubiprostone) and Motegrity (prucalopride) for chronic idiopathic constipation. A large-pharma incumbent in the same therapeutic category with global commercial reach that Vibrant must compete against for prescriber mindshare.

Emerging players

• Mahana Therapeutics: Mahana Therapeutics is a digital therapeutics company focused on gastrointestinal conditions including IBS, with FDA-authorized prescription digital therapeutics. Comparable as a non-drug, evidence-based, prescription therapeutic competing for the same dissatisfied CIC/IBS patient population.
• Cara Care (formerly Bold Health): Cara Care is a digital therapeutics and digestive health platform offering app-based behavioral therapy for IBS and other functional GI disorders. Comparable as a non-prescription-drug, digital-first therapeutic alternative addressing CIC/IBS symptom management.
• Atmo Biosciences: Atmo Biosciences is developing an ingestible gas-sensing capsule for GI motility and functional gut disorders. Comparable as an emerging player in the ingestible-capsule diagnostic/therapeutic category with overlapping GI indications and target prescriber base.
• Vivante Health: Vivante Health is a digital health platform combining GI-specialized care navigation, nutrition, and behavioral support for digestive conditions. Comparable as an emerging non-drug alternative addressing CIC and IBS patients seeking drug-free management.

Others

• Medtronic: Medtronic markets InterStim sacral nerve stimulation for bowel dysfunction including fecal incontinence and overactive bowel. Adjacent, established neuromodulation device company in GI/pelvic-floor disorders — relevant for understanding how device-based neuromodulation achieves payer coverage and clinician adoption over time.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vibrant Gastro